Evidence map›Paper›PMID 33081606›Full record

ArticleTherapeutic advances in respiratory disease

Effect of once-daily fluticasone furoate/vilanterol

Francois Maltais, Isabelle Schenkenberger, Pascal L M L Wielders, Juan Ortiz de Saracho, Kenneth Chinsky, Michael Watkins, Valerie Millar, Courtney Crim

Open access · goldAbstract readEquivalence TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 4 pooled it
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD.European respiratory review : an official journal of the European Respiratory Society · 2021
    Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 6 countries.

Francois MaltaisCentre de Recherche, Institut universitaire de cardiologie et de pneumologie de Québec, 2725 Chemin Sainte Foy, Québec City, QC, G1V 4G5, Canada.ORCID 0000-0002-6809-4651
Isabelle SchenkenbergerKlinische Forschung Berlin GbR, Berlin, Germany.
Pascal L M L WieldersDepartment of Pulmonary Diseases, Catharina Hospital, Eindhoven, The Netherlands.
Juan Ortiz de SarachoDepartment of Pulmonary Diseases, El Bierzo Hospital, Ponferrada (León), Spain.
Kenneth ChinskyChest Diseases of Northwestern PA, Erie, PA, USA.
Michael WatkinsRespiratory Research and Development, GlaxoSmithKline plc., Research Triangle Park, NC, USA.
Valerie MillarBiostatistics, GlaxoSmithKline plc., Uxbridge, UK.
Courtney CrimResearch and Development, GlaxoSmithKline plc., Research Triangle Park, NC, USA.
Research Triangle Park Foundation · USGesellschaft für Klinische Forschung · DEGlaxoSmithKline (United Kingdom) · GBHospital El Bierzo · ESInstitut universitaire de cardiologie et de pneumologie de Québec · CARadboud University Nijmegen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe relationship between inhaled corticosteroids and bone mineral density (BMD) remains uncertain despite extensive research.

methodsThis was an international, multicenter, randomized, double-blind, parallel-group, 3-year noninferiority study. Patients with chronic obstructive pulmonary disease (COPD) (⩾40 years of age; smoking history ⩾10 pack years) and at least one native hip evaluable for BMD were enrolled and randomized 1:1, stratified by sex, to treatment with vilanterol (VI) 25 µg or fluticasone furoate/vilanterol (FF/VI) 100 µg/25 µg. BMD measurements were taken

resultsOf 283 randomized patients, 170 (60%) completed the study. Noninferiority was demonstrated for FF/VI

conclusionFF/VI showed noninferiority to VI for change from baseline in total hip BMD per year, when assessed at the -1% noninferiority margin in a combined sample of men and women with COPD.

Indexed as

Administration, InhalationAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAgedAndrostadienesBenzyl AlcoholsBone DensityCanadaChlorobenzenesDouble-Blind MethodDrug Administration ScheduleDrug CombinationsEuropeFemaleHumansLungAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAndrostadienesBenzyl AlcoholsChlorobenzenesDrug Combinationsfluticasone furoatevilanterolbone densitychronic obstructive pulmonary diseasefracturesinhaled corticosteroidslumbar spine

Identifiers

PMID33081606
PMCPMC7798365
OpenAlexW3093952199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.